-

SQZ Biotechnologies to Present at Upcoming Investor Conferences

WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies (NYSE: SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today announced that Armon Sharei, Ph.D., Chief Executive Officer and Founder of SQZ Biotechnologies, will present at the 21st Annual Needham Virtual Healthcare Conference on April 13, and Chardan’s 6th Annual Genetic Medicines & Cell Therapy Manufacturing Summit on April 26. Presentation times and webcast information are available below.

PRESENTATION DETAILS

Wednesday, April 13
21st Annual Needham Virtual Healthcare Conference
9:30-10:10 am ET
Webcast

Tuesday, April 26
Chardan’s 6th Annual Genetic Medicines & Cell Therapy Manufacturing Summit
10:00-10:25 am ET
Webcast

Conference webcast details and the company’s most recent corporate overview presentation will be available on the Investors section of the SQZ website.

About SQZ Biotechnologies
SQZ Biotechnologies Company is a clinical-stage biotechnology company focused on unlocking the full potential of cell therapies for patients around the world and has active programs in Oncology, Autoimmune and Infectious Diseases, as well as additional exploratory initiatives to support future pipeline growth. The company’s proprietary Cell Squeeze® technology offers the unique ability to deliver multiple biological materials into many cell types to engineer what we believe can be a broad range of potential therapeutics. With demonstrated production timelines under 24 hours and the opportunity to eliminate preconditioning and lengthy hospital stays, our approach could significantly broaden the therapeutic range and accessibility of cell therapies. The company’s first therapeutic applications seek to generate target-specific immune responses, both in activation for the treatment of solid tumors and infectious diseases, and in immune tolerance for the treatment of autoimmune diseases. For more information, please visit www.sqzbiotech.com.

Contacts

Investor Contact:
Mike Kaiser
michael.kaiser@sqzbiotech.com
857-760-0398

Media Contact:
John Lacey
john.lacey@sqzbiotech.com
781-392-5514

SQZ Biotechnologies

NYSE:SQZ

Release Versions

Contacts

Investor Contact:
Mike Kaiser
michael.kaiser@sqzbiotech.com
857-760-0398

Media Contact:
John Lacey
john.lacey@sqzbiotech.com
781-392-5514

More News From SQZ Biotechnologies

Asset Sale and Plan of Liquidation and Dissolution Approved by SQZB Shareholders

WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies Company (OTC: SQZB) (the “Company” or “SQZ”) today announced the results for the proposals considered and voted upon by its shareholders at its special meeting on February 29, 2024 (the “Special Meeting”). The Company reported that all of the proposals submitted to its shareholders in connection with the previously announced asset sale pursuant to that certain Asset Purchase Agreement (the “Purchase Agreement”), dated December 21, 2023, ent...

SQZ Biotechnologies Reports Third Quarter 2023 Financial Results and Recent Portfolio Updates

WATERTOWN, Mass.WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies Company (OTC: SQZB), focused on unlocking the full potential of cell therapies, today reported third quarter 2023 financial results and recent portfolio updates. “We have taken difficult, but necessary, steps to reduce our operating expenses as we explore strategic alternatives,” said Howard Bernstein, M.D., Ph.D., Interim Chief Executive Officer and Member of the Board of Directors. “The Management Team and the Board firmly...

SQZ Biotechnologies Reports Data for Clinical Programs at the Society for Immunotherapy of Cancer Annual Meeting

WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies Company (OTC: SQZB), focused on unlocking the full potential of cell therapies, presented clinical data for three programs focused on the treatment of Human Papillomavirus 16 positive (HB16+) driven cancers at the Society for Immunotherapy of Cancer Annual Meeting 2023. “Our programs have shown a favorable safety profile and the ability to effect clinical benefit for patients,” said Howard Bernstein, M.D., Ph.D., Interim Chief Executive Off...
Back to Newsroom